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Abstract
Background: Among cancer patients, prior antidepressant use has been associated with impaired survival. This
could be due to differences in stage at diagnosis, in receipt of treatment, or in treatment complications. The
purpose of this study was, therefore, to examine if preadmission antidepressant use in patients with bladder
cancer is associated with tumor stage at diagnosis, rate of cystectomy, and surgical outcomes, including survival.
Methods: We performed a registry-based cohort study including all patients with incident invasive bladder
cancer in Denmark 2005–2015. Exposure was defined as redemption of two or more antidepressant prescriptions
one year before cancer diagnosis. We compared tumor stage using logistic regression, postsurgical inpatient
length of stay using linear regression, and other outcomes using Cox regression. All results were adjusted for age,
sex, comorbidity, and marital status.
Results: Among 10,427 bladder cancer patients, 10% were antidepressant users. At diagnosis, 51% of users and
52% of non-users had muscle-invasive disease. However, upon adjustment for age, sex, comorbidity, and marital
status, users had lower odds of muscle-invasive disease (adjusted odds ratio 0.86 (95% confidence interval (CI) 0.
74–0.99)). Among patients with muscle-invasive disease, fewer users than non-users had surgery within three
months (15% vs. 24%, adjusted hazard ratio (aHR) 0.75 (95% CI 0.59–0.95)). Of 2532 patients undergoing surgery,
6% were antidepressant users. Postsurgical inpatient length of stay did not differ between users and non-users.
The 30-day cumulative incidence of readmission was higher for users (41% vs. 33%, aHR 1.33 (95% CI 1.05–1.67)),
while the 90-day incidence of postoperative procedures was 44% for users and 38% for non-users (aHR 1.18 (95%
CI 0.93–1.51)). One-year mortality was comparable in users (15%) and non-users (14%).
Conclusions: Antidepressant use in bladder cancer patients was associated with less advanced stage at diagnosis
and lower rate of cystectomy. After cystectomy, users had higher rate of readmission and postoperative procedures
than non-users, but we found no difference in length of stay or one-year mortality. The results point to the importance
of differentiated clinical care according to individual patient characteristics.
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Background
As the ninth most commonly diagnosed cancer worldwide,
bladder cancer caused a reported 165,000 deaths globally
in 2012 [1]. Recommended standard treatment for muscle-
invasive and high-risk non-muscle-invasive tumors is rad-
ical cystectomy, a procedure with 30-day complication
rates between 24% and 73% [2]. Comorbidity raises compli-
cation risk [3], and bladder cancer patients are increasingly
comorbid [4], with increased medication use including an-
tidepressants as a consequence. The overall use of antide-
pressants increased by a mean of 40 defined daily doses/
1000/day across Europe in the period 1980–2009 [5].
Although increasingly prescribed for neuropathic pain
and sleep disorders, antidepressants are mostly prescribed
for depression [6]. In a Danish setting, use of antidepres-
sants detects patients suffering from a depression with a
specificity of 94% to 97% [7]. This makes prescription data
about antidepressants suited for identification of patients
with depression in Denmark, where more than 90% of
such patients are treated by general practitioners [7]; the
treatment in these cases is not recorded in hospital
registries.
In a recent Danish cohort study of patients with various
types of cancer, prior antidepressant use was associated
with a 30% increase in one-year mortality [8]. The study
supports prior studies reporting an elevated mortality in
patients with depression who developed various cancers
[9–11], pancreatic cancer [12], colon cancer [13], or pros-
tate cancer [14]. Diagnostic delay, reduced likelihood of
appropriate treatment, or treatment complications may
explain an increased mortality in antidepressant users.
However, studies of delay in diagnosis of breast, prostate,
colorectal, bladder, lung, skin, uterine, and pancreatic can-
cer for patients with depression show conflicting results
[8–10, 12]. Prior antidepressant use was not associated
with more advanced bladder cancer stage in the recent
Danish work [8]. Although previous studies have reported
a lower likelihood of appropriate cancer treatment in pa-
tients with prior or existing depression in a number of
cancers combined [9], as well as pancreatic [12], colon
[13], or prostate cancer [14], this has not been examined
in patients with bladder cancer. The reported increase in
one-year mortality among patients with cancer who used
antidepressants before cancer diagnosis [8] is of concern
and more detailed studies are needed to clarify underlying
mechanisms.
Therefore, the aim of this nationwide population-based
cohort study was to investigate whether antidepressant
use initiated before invasive bladder cancer diagnosis was
associated with more advanced cancer at time of diagnosis
or time of surgery, lower rate of cystectomy, and a more
complicated postoperative course reflected in length of
hospital stay, readmission, postoperative procedures and
mortality.
Methods
We performed a nationwide register-based cohort study
including all patients diagnosed with incident invasive
bladder cancer in Denmark from 2005 through 2015. The
Danish population, approximately 5.6 million inhabitants,
has access to tax-supported healthcare, with free access to
hospital-based and primary medical care provided by the
Danish National Health Service [15]. All inhabitants in
Denmark have a unique Civil Personal Register (CPR)
number, which is recorded along with administrative and
medical information in registries and databases and allows
for person-specific linkage of information [16].
Data sources
From the Danish National Patient Registry (DNPR), we re-
trieved diagnosis and procedure codes and associated
dates. The DNPR has tracked all somatic hospitalizations
in Denmark since 1977 and outpatient and emergency
room visits to hospitals since 1995. Recorded data include
CPR numbers, dates of admission and discharge, and up
to 20 diagnoses, classified according to the International
Classification of Diseases, tenth revision (ICD-10) since
1994 [17]. We ascertained information on tumor path-
ology from The Danish National Pathology Registry,
which contains descriptions of pathological specimens
and has a coverage of almost 100% [18]. The registry was
established in 1997, and data from earlier years have been
added [18]. We defined exposure status using data from
the Danish National Database of Reimbursed Prescrip-
tions [19]. This registry encompasses information on all
redeemed prescriptions from 2004 onwards, including
date of redemption and Anatomical Therapeutic Chemical
(ATC) code. Finally, the Danish Civil Registration System
provided data on marital and vital status. This database
contains nearly complete, demographic data and is up-
dated daily [16].
Study population
We identified patients with incident, histologically veri-
fied invasive bladder cancer (thus not including patients
with carcinoma in situ or pTa tumors) based on ICD-10
diagnosis codes (C67) and bladder cancer pathology
(Additional file 1: Table S1). To increase the probability
of truly incident cases we excluded patients fulfilling
these criteria between 1995 and 2004.
For the surgical outcome analyses, we identified patients
with bladder cancer and a recorded cystectomy excluding
patients who received intended curative radiation therapy
before cystectomy (Additional file 1: Table S1).
Exposure, outcome measures, and covariates
We defined individuals as exposed (‘antidepressant users’)
if they filled two or more antidepressant prescriptions
(ATC code N06A) on separate occasions in the year
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preceding bladder cancer diagnosis. Using this definition
we sought to reduce the number of non-adherent patients
in the exposure group. Individuals filling one prescription
or less are termed ‘non-users’. Patients who filled an anti-
depressant prescription after bladder cancer diagnosis, but
not in the year before, were treated as non-users.
Stage at diagnosis was defined as muscle-invasive (pT2
+) or non-muscle-invasive (pT1), and stage at cystec-
tomy as organ confined (pT0-T2 and pN0) or non-organ
confined (pT3-T4 or pN+).
We compared the cumulative incidence of cystectomy
within three months following a diagnosis of
muscle-invasive disease. We chose three months as a clin-
ically relevant end of follow-up based on prior work [20].
Following surgery, we assessed outcomes expected to re-
flect a complicated postsurgical course: length of hospital
stay, acute readmission to a somatic hospital within
30 days after discharge from the primary admission,
90-day rate of postoperative procedures, and all-cause
mortality at one and three years. We defined postoperative
procedures as any invasive procedure within 90 days after
cystectomy (any NOMESCO Classification of Surgical
Procedures code).
Based on existing literature we included as potential
confounders: age, sex, marital status at diagnosis, Charl-
son Comorbidity Index (CCI) score [21] (excluding blad-
der cancer), and alcohol-related disorders. We identified
comorbidities from DNPR within 10 years before cancer
diagnosis (Additional file 2: Table S2) [22].
Statistical methods
Patients’ characteristics at bladder cancer diagnosis were
summarized according to exposure groups. Continuous
variables were either categorized or described by their me-
dian value and interquartile range. For categorical vari-
ables, we computed proportions of individuals at each
categorical level by exposure group.
We examined the association between antidepressant
use and stage at diagnosis (muscle-invasive (pT2+) or
non-muscle-invasive (pT1)) or surgery (organ confined
(pT0-T2 and pN0) or non-organ confined (pT3-T4 or
pN+)) using logistic regression, adjusting for age at diag-
nosis (included as an unrestricted spline with four knots
in the analysis of stage at diagnosis and squared in stage
at surgery), sex, CCI score (0, 1–2, 3+), alcohol-related
disorders (yes/no), and marital status at diagnosis (mar-
ried/not married). The analysis of stage at surgery ex-
cluded patients receiving neoadjuvant chemotherapy,
which was introduced nationwide in Denmark in 2013
(Additional file 1: Table S1).
Due to missing data for tumor stage at diagnosis and
at surgery, two sensitivity analyses were performed to in-
crease the proportion of individuals with stage data: we
restricted the analysis of stage at diagnosis to patients
diagnosed during 2011–2015, and we repeated the ana-
lysis of stage at surgery including the latest stage re-
corded before surgery, if stage at surgery was missing.
For the analysis of time to surgery, we followed pa-
tients not receiving neoadjuvant chemotherapy from
the date on which muscle invasiveness was first de-
tected until cystectomy, death, emigration, end of the
three months of follow-up, or 11 April 2016, whichever
came first. Follow-up for postoperative procedures
began at date of surgery while follow-up for readmis-
sion began at discharge. For both events, follow-up
ended at event of interest, death, emigration, end of the
30-day or 90-day follow-up, or 11 April 2016, which-
ever came first.
We computed the cumulative incidence of cystectomy
and used Cox proportional hazards regression to investi-
gate the association between antidepressant use and
cystectomy. Here, death and curative-intended radiation
therapy were treated as competing risks.
We used Cox proportional hazards regression to in-
vestigate associations between antidepressant use and re-
admission and postoperative procedures adjusting as
described for the logistic regression of stage at surgery.
Death was considered competing risk. Length of hospital
stay was compared between groups using a multiple lin-
ear regression model including covariates as in the logis-
tic regression of stage at diagnosis.
For the mortality analysis, we followed patients from
date of surgery until death, emigration, end of the one-
year or three-year follow-up or 19 April 2016, whichever
came first. We used the Kaplan-Meier estimator and com-
pared mortality using Cox regression adjusting as de-
scribed for the logistic regression of stage at surgery.
Additionally, we investigated whether neoadjuvant
chemotherapy, stage at surgery, and type of surgery (open
or laparoscopic and robot-assisted, (Additional file 1:
Table S1)) mediated surgical outcome differences between
exposure groups by addition of each of these variables in-
dividually to the regression models described above.
For all Cox regressions, the assumption of propor-
tional hazards was assessed by log-minus-log plots.
All analyses were performed using Stata version 14
(StataCorp LP, College Station, Texas).
Results
We identified 10,427 patients with incident invasive
bladder cancer during 2005 through 2015 (Fig. 1). In the
cohort, 1079 (10%) were antidepressant users. At presen-
tation, antidepressant users were less likely to be married
and had more comorbidity than non-users (Table 1).
Stage at diagnosis and at surgery
At diagnosis, analysis of data from 79% of patients for
whom pT stage data were available showed comparable
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proportions of muscle-invasive disease in antidepressant
users and non-users, but upon adjustment, antidepressant
users had lower odds of muscle-invasiveness compared
with non-users (adjusted odds ratio 0.86 (95% CI 0.74–
0.99)) (Table 2). Restricting the analysis to patients di-
agnosed during 2011 through 2015, where 93% had
stage information, yielded an adjusted odds ratio of
0.87 (95% CI 0.71–1.05).
At cystectomy, 62% of antidepressant versus 57% of
non-users had non-organ confined disease (Table 3).
The adjusted odds ratio for non-organ confined disease
was 1.16 (95% CI 0.78–1.74) in the 71% of patients with
tumor-stage information at surgery. Additionally adjust-
ing for time to surgery yielded an odds ratio of 1.18
(95% CI 0.79–1.77). Replacing missing values with the
latest stage recorded before surgery resulted in an ad-
justed odds ratio of 1.19 (95% CI 0.84–1.69).
Time to surgery
We identified 4953 patients with muscle-invasive bladder
cancer. The cumulative incidence of cystectomy within
three months from the date on which muscle invasiveness
was first detected was lower for antidepressant users than
1815 with 
coinciding C67 and 
IBC pathology
1995-2004
10,427 with incident 
coinciding C67 and IBC 
pathology
2005-2015
2196 without 
coinciding C67 and 
IBC pathology
1995-2015
14,438 individuals
with C67 in DNPR
2005-2015
2594
underwent cystectomy
62 treated 
with intended 
curative radiation 
therapy
2532 underwent 
cystectomy without prior 
intended curative radiation 
therapy
12,242 with
coinciding C67 and IBC 
pathology
1995-2015
Fig. 1 Flow diagram of the study population. DNPR: The Danish
National Patient Registry. IBC: invasive bladder cancer
Table 1 Patient characteristics at diagnosis according to use of
antidepressants before cancer diagnosis
Non-users AD users
n % n %
Total 9348 89.7 1079 10.3
Median age (IQR) (years) 72.5 66.0–79.8 74.4 67.8–82.3
Age group (years)
18–49 224 2.4 22 2.0
50–59 814 8.7 85 7.9
60–69 2554 27.3 235 21.8
70–79 3475 37.2 378 35.0
80- 2281 24.4 3539 33.3
Sex
Male 7036 75.3 647 60.0
Female 2312 24.7 432 40.0
Marital status
Married 5549 59.4 532 49.3
Widowed 1836 19.6 320 29.7
Divorced 1233 13.2 145 13.4
Never married 730 7.8 82 7.6
Charlson Comorbidity Index score
Low (0) 4703 50.3 334 31.0
Medium (1–2) 3124 33.4 437 40.5
High (3+) 1521 16.3 308 28.5
Alcohol-related disorders 191 2.0 68 6.3
Year of cancer diagnosis
2005–2007 2563 27.4 271 25.1
2008–2010 2555 27.3 283 26.2
2011–2013 2527 27.0 314 29.1
2014–2015 1703 18.2 211 19.6
Stage of cancer at diagnosis
Non-muscle-invasive (pT1) 3538 37.8 423 39.2
Muscle-invasive (pT2+) 3854 41.2 437 40.5
Missing 1956 20.9 219 20.3
Cystectomy 2370 25.4 162 15.0
Neoadjuvant chemotherapy 222 9.4 15 9.3
Intended curative radiation therapy 1145 12.3 114 10.6
All patients (n = 10,427) were diagnosed with incident invasive bladder cancer
during 2005 through 2015. AD antidepressant, IQR interquartile range
Steffensen et al. BMC Cancer         (2018) 18:1035 Page 4 of 9
non-users (Fig. 2). The difference remained apparent after
adjustment (adjusted hazard ratio 0.75 (95% CI 0.59–
0.95)) (Table 4).
Surgical outcomes
We identified 2532 cystectomies of which 698 (27.6%)
were robot-assisted. Among cystectomized patients,
162 (6%) were antidepressant users. Table 5 presents
estimates of associations between antidepressant use
and surgical outcomes. Median follow up from surgery
to death, loss to follow up, or end of study was
2.6 years (interquartile range 1.1 to 5.5 years).
Median duration of postsurgical stay did not differ be-
tween antidepressant users and non-users.
With a cumulative incidence of 41%, antidepressant
users were more likely to be acutely readmitted within
30 days after discharge, compared with non-users (ad-
justed hazard ratio 1.33 (95% CI 1.05–1.67)). We
observed no difference in type of department for re-
admission between antidepressant users and non-users
(results not shown). The diagnoses related to readmis-
sion were similar among exposure groups and largely
reflected postoperative complications (results not
shown).
Antidepressant users’ 90-day cumulative incidence of
postoperative procedures was 44% compared with 38%
among non-users (adjusted hazard ratio 1.18 (95% CI
0.93–1.51)). The types of postoperative procedures
were comparable among antidepressant users and
non-users and mainly represented procedures related
to complications to the cystectomy and urinary diver-
sion—the five most common being: percutaneous
nephrostomy, repair of wound dehiscence in urological
surgery, percutaneous drainage of intraperitoneal ab-
scess, percutaneous drainage of peritoneal cavity, and
nephrostomy.
Overall one-year all-cause mortality after surgery was
14.5% (95% CI 13.1–15.9%). One- and three-year mortal-
ity showed no difference between exposure groups after
adjustment.
Repeating all surgical outcome analyses additionally
adjusting for neoadjuvant chemotherapy, stage at cystec-
tomy, or type of surgery changed estimates by less than
5% (Additional file 3: Table S3).
Discussion
In this nationwide population-based cohort study, we
found that patients with bladder cancer who filled at least
two antidepressant prescriptions in the year before cancer
diagnosis were less likely to present with muscle-invasive
disease at diagnosis (i.e. they had lower odds of muscle-in-
vasive disease relative to non-users upon adjustment).
Users also had a lower rate of cystectomy in case of
muscle-invasive disease. Following surgery, antidepressant
users and non-users had comparable length of stay. How-
ever, we observed a slightly higher risk of postoperative
procedures within 90 days and a higher 30-day readmis-
sion rate after surgery in antidepressant users than in
non-users. Still, users’ all-cause mortality was not different
from non-users at one and three years.
We observed similar proportions of patients with
muscle-invasive cancer at diagnosis among antidepressant
users and non-users. However, this observation was likely
confounded since antidepressant users had lower odds of
Table 2 Odds ratios for muscle-invasive bladder cancer at diagnosis comparing antidepressant users to non-users
Complete case analysis 2011–2015
Muscle-invasive (pT2+) Non-muscle-invasive (pT1) Unadjusted
odds ratio
(95% CI)
Adjusteda
odds ratio
(95% CI)
Unadjusted
odds ratio
(95% CI)
Adjusteda
odds ratio
(95% CI)
n % n %
Non-users (n = 7392) 3854 52.1 3538 47.9 Ref. Ref. Non-users (n = 3938) Ref. Ref.
AD users (n = 860) 437 50.8 423 49.2 0.95
(0.82–1.09)
0.86
(0.74–0.99)
AD users (n = 490) 0.96
(0.79–1.16)
0.87
(0.71–1.05)
Results of complete case analysis (2005–2015) and when restricting the analysis to 2011 through 2015. AD antidepressant, CI confidence interval. aAdjusted for
age, sex, CCI, alcohol-related disorders, and marital status
Table 3 Odds ratios for non-organ confined cancer at cystectomy comparing antidepressant users to non-users
Complete case analysis Including prior stages
Non-organ confined
(pT3-T4 or pN+)
Organ confined
(pT0-T2 and pN0)
Unadjusted
odds ratio
(95% CI)
Adjusteda
odds ratio
(95% CI)
Unadjusted
odds ratio
(95% CI)
Adjusteda
odds ratio
(95% CI)n % n %
Non-users (n = 1521) 859 56.5 662 43.5 Ref. Ref. Non-users (n = 2081) Ref. Ref.
AD users (n = 111) 69 62.2 42 37.8 1.27
(0.85–1.88)
1.16
(0.78–1.74)
AD users (n = 142) 1.29 (0.92–1.81) 1.19
(0.84–1.69)
Results of complete case analysis and when replacing missing values for cancer stage with the latest stage observed before surgery. AD antidepressant, CI
confidence interval. aAdjusted for age, sex, CCI, alcohol-related disorders, and marital status
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muscle-invasive disease upon adjustment for age, sex, co-
morbidity, and marital status. Our result is unexpected
since depression has been associated with advanced stage
at cancer presentation [8, 12]. One possible explanation is
an enhanced likelihood of cancer detection due to in-
creased utilization of health care by antidepressant users
[23]. Study setting may add to this: access to the
tax-funded Danish health care services is free [15], minim-
izing the risk of patient delay in diagnosis due to patients’
financial situation or constraints. However, Sun et al.
found that Danish patients with breast, colorectal, or pros-
tate cancer who were using antidepressants presented in
an advanced stage [8]. This suggests that mechanisms
underlying diagnostic delay may differ between cancer
types. In bladder cancer, hematuria may be so concerning
to patients that it leads to cancer diagnosis even if patients
are impaired by depression. In other cancers, symptoms
may be less alarming, or perhaps symptoms are consid-
ered caused by depression, leading to a diagnostic delay in
patients with depression who develop cancer.
Previous studies have found a lower likelihood of treat-
ment in cancer patients with prior depression [9, 12–14].
This is in line with our finding of antidepressant users’
lower rate of cystectomy. Patient-related factors associated
with decline of curative cancer treatment include patients’
perceived low quality of patient-physician communication
[24], concern about side effects [25], and expected low
quality of life after surgery [24] all of which may be exag-
gerated in antidepressant users. Another explanation
could be that a larger proportion of antidepressant users
than non-users received palliative care rather than radical
cystectomy. We must note, however, that we did not have
information on all clinical features and patient characteris-
tics contributing to treatment decision.
We observed a high rate of postoperative proce-
dures compared with prior studies reporting 90-day
reoperation rates in the range 14–33% [2]. The dis-
crepancy is likely explained by the fact that we in-
cluded all types of procedures (not solely
complication related procedures) performed 90 days
after cystectomy. We note that the estimate in this
analysis is somewhat imprecise, given that the 95%
confidence interval includes one. Higher rates of re-
admission and, potentially, postoperative procedures
among antidepressant users suggest a more compli-
cated postsurgical course, while the lack of difference
in length of stay speaks against any major difference.
In prior studies, surgical patients with depressive
symptoms had impaired wound healing and higher
risk of infections [26, 27]. Our results are consistent
with these findings, if antidepressant users had de-
pressive symptoms at the time of surgery.
0 25 50 75 100 125
Days since first detection of muscle-invasive cancer
Non-users Antidepressant users
95% CI 95% CI
y
motcetsyc
fo
ytilib abor
P
52.
2.
51.
1.
50.
0
Fig. 2 Cumulative incidence of cystectomy within three months from the first detection of muscle-invasive disease. CI: Confidence interval
Table 4 Cumulative incidence and hazard ratio of cystectomy for patients with muscle-invasive disease comparing antidepressant
users to non-users
Cystectomized, n Three months cumulative incidence, % (95% CI) Unadjusted HR (95% CI) Adjusteda HR (95% CI)
Non-users (n = 4443) 1082 24.3 (23.1–25.6) Ref. Ref.
AD users (n = 510) 76 14.7 (11.8–18.0) 0.60 (0.48–0.76) 0.75 (0.59–0.95)
The cumulative incidence and hazard ratio of cystectomy is determined within three months from the first detection of muscle-invasive disease. AD
antidepressant, HR hazard ratio, CI confidence interval. aAdjusted for age, sex, CCI, alcohol-related disorders, and marital status
Steffensen et al. BMC Cancer         (2018) 18:1035 Page 6 of 9
In contrast to prior work [8], we did not observe an
association between antidepressant use and all-cause
mortality in patients with cancer. Possible explanations
may be that we restricted the survival analysis to pa-
tients undergoing surgery and that selection for surgery
differed between antidepressant users and non-users.
Antidepressant users and non-users who underwent sur-
gery are a selected group of patients with bladder cancer.
Differences in comorbidity are likely to be equalized be-
cause of the selection resulting in comparable survival.
Also, Sun et al. [8] found that the increased mortality
among antidepressant users depended on time of
antidepressant initiation. This may contribute to the dis-
crepancy between our studies. Another aspect to consider
is severity of depression: generally, antidepressant users
were probably less severely depressed than individuals in-
cluded in earlier studies based on secondary psychiatric
care data [10, 11], because these previous studies did not
include patients with milder depression treated by general
practitioners.
A strength of the current study is that by using register
data, we were able to include all patients in Denmark with
invasive bladder cancer during the study period. Also, we
were able to control for differences in comorbidity in con-
trast to previous studies [9, 10]. We did not rely on
self-report of exposure and we achieved essentially
complete follow-up, thereby increasing generalizability.
To reduce the risk of misclassification due to medication
non-adherence, we required the exposed patients to have
filled at least two prescriptions for antidepressants.
The study results must, however, be interpreted bearing
in mind a number of limitations. Our analyses did not
take into account indications for readmission and postop-
erative procedures. However, we only observed small dif-
ferences between antidepressant users and non-users in
types of postoperative procedures and readmission, and
most procedure codes and readmission diagnosis codes
reflected complications related to cystectomy.
We emphasize that use of antidepressants does not
always indicate depression, since antidepressants are
sometimes prescribed for other conditions. As such, our
findings may not be directly comparable to studies in-
vestigating patients with a depression diagnosis. Also,
some non-users may have suffered from a depression
not treated by antidepressants. This could weaken asso-
ciations between antidepressant use and outcomes such
as time to cystectomy or postoperative outcomes. Prior
studies based on a diagnosis of depression might have
experienced a comparable misclassification of exposure
due to undiagnosed depression or depression not re-
corded in registries [9–14].
We note that antidepressant users were generally more
comorbid than non-users; a potential confounding effect
we accounted for by adjusting for CCI. However, we cannot
rule out the possibility of residual confounding due to e.g.
comorbidity not recorded in registries. Also, we lacked in-
formation on certain additional potential confounders, such
as detailed clinical characteristics, smoking, alcohol use,
and socioeconomic status. A previous study, however,
found no clear association between socioeconomic status
and radical cystectomy [28]. Although we restricted the
analysis of time to surgery to patients with muscle-invasive
disease, we cannot rule out that exposure groups differed
with regard to lymph node status and/or distant metastases.
If more antidepressant users had distant metastases, this
could explain their lower rate of cystectomy. However,
Table 5 Surgical outcomes among patients undergoing radical
cystectomy by antidepressant use before cancer diagnosis
Surgical outcome Non-users AD users
Length of stay (LOS)
Days admitted, median
(IQR)
10 (7–13) 9 (8–13)
Unadjusted ratio of median LOS
(95% CI)
Ref. 1.03 (0.95–1.13)
Adjusteda ratio of median LOS
(95% CI)
Ref. 1.02 (0.93–1.12)
30-day acute readmission
Total, n 2241 151
Readmitted, n 747 62
Cumulative incidence, % (95% CI) 33.4 (31.4–35.3) 41.1 (33.2–48.8)
Unadjusted HR (95% CI) Ref. 1.36 (1.08–1.71)
Adjusteda HR (95% CI) Ref. 1.33 (1.05–1.67)
90-day postoperative procedure
Total, n 2370 162
Procedures, n 908 72
Cumulative incidence, % (95% CI) 38.3 (36.4–40.3) 44.4 (36.7–51.9)
Unadjusted HR (95% CI) Ref. 1.19 (0.93–1.51)
Adjusted* HR (95% CI) Ref. 1.18 (0.93–1.51)
One-year all-cause mortality
Total, n 2370 162
Deaths, n 330 24
Cumulative incidence, % (95% CI) 14.4 (13.1–16.0) 15.0 (10.3–21.6)
Unadjusted HR (95% CI) Ref. 1.05 (0.69–1.58)
Adjusteda HR (95% CI) Ref. 0.96 (0.63–1.46)
Three-year all-cause mortality
Total, n 2370 162
Deaths, n 650 52
Cumulative incidence, % (95% CI) 31.3 (29.3–33.4) 35.4 (28.1–43.8)
Unadjusted HR (95% CI) Ref. 1.16 (0.88–1.54)
Adjusteda HR (95% CI) Ref. 1.02 (0.77–1.36)
The analysis of acute readmission excludes patients with a primary admission
longer than 30 days (n = 140). AD antidepressant, IQR interquartile range, CI
confidence interval, HR hazard ratio. aAdjusted for age, sex, CCI, alcohol-related
disorders, and marital status
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antidepressant users had less advanced cancer at diagnosis,
suggesting that they were not more likely to have metasta-
ses compared with non-users. Moreover, we did not ob-
serve any mortality difference between groups, which
would have been expected in case of unequal proportions
of patients with distant metastases. Smoking increases the
risk of surgical complications [29], and may in part con-
found our findings on readmission and postoperative pro-
cedures. However, estimates changed very little upon
adjustment for other covariates (age, sex, comorbidity, and
marital status). This leads us to believe that confounding by
smoking does not completely explain the observed associa-
tions. Smoking is associated with more advanced stage of
bladder cancer at diagnosis [30]. Thus, if antidepressant
users were more often smokers, the lower stage at diagnosis
observed among them would be unexpected. On the other
hand, if antidepressant users were less often smokers, our
observation of no difference in mortality after surgery could
be confounded by smoking. Altogether, we cannot exclude
the possibility that the inability to adjust for smoking leads
to residual confounding.
Our findings suggest that patients with bladder cancer
using antidepressants before diagnosis may be a subgroup
worth special attention—especially in relation to receipt of
treatment and postsurgical care. This also points to the
importance of differentiated clinical care according to in-
dividual characteristics and individual needs. For example,
patients with high levels of comorbidities preoperatively,
dementia, depression, etc. are subgroups who we should
devote more effort to in terms of preoperative preparation
and closer postoperative care following discharge. In line
with this, future studies may focus on other patient sub-
groups and evaluate aspects in relation to receipt of treat-
ment and treatment outcomes as such knowledge is a
prerequisite for individualized clinical care.
Conclusions
In conclusion, this nationwide population-based cohort
study using Danish register data found that antidepressant
use before invasive bladder cancer diagnosis was associ-
ated with less advanced stage of cancer at diagnosis.
Among patients with muscle invasive disease, we observed
lower rate of cystectomy in antidepressant users, and after
surgery higher rate of readmission and, potentially, higher
rate of postoperative procedures, but not prolonged length
of stay or increased all-cause mortality. Our findings indi-
cate that antidepressant users who develop bladder cancer
may require increased medical attention.
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